Project Grant HT94252310821
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The University Health Network (UHN) in Toronto, Canada was awarded a $303,156 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct a study on "LINEAGE TRACING IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND PLEXIFORM NEUROFIBROMAS TO ASSESS TUMORAL HETEROGENEITY AND MECHANISMS OF DRUG RESISTANCE". The award, which runs from June 1, 2024 to May 31, 2026, will support UHN's cutting-edge biomedical research focused...
The University Health Network will receive $611,415 under a three-year Project Grant award from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care. Under this award, the University Health Network will conduct research from August 2022 to August 2025 to identify novel immune evasion tumor immune networks...
The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...
The federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $807,400.00 to the Provincial Health Services Authority (BC Cancer) in Canada. The grant, awarded on May 1, 2024, supports a research project titled "DECODING HOW DISTINCT MECHANISMS OF GENOMIC INSTABILITY FOUND IN TNBC PATIENTS PROGRAM THE TISSUE MICROENVIRONMENT AND THERAPY RESPONSE AT METASTATIC SITES." This project aims to investigate...
The University Health Network will receive $1,419,453 under a Project Grant award from the Department of the Army Medical Command to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. Funded through the Military Medical Research and Development program (CFDA 12.420), this four-year award beginning September 1, 2022 will support applied research investigating medical solutions for neuroblastoma on the battlefield and...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...
The Defense Health Agency awarded a $999,540.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Governing Council of the University of Toronto, operating as the University of Toronto, to examine the link between hippocampal pathology and meningeal inflammation in progressive multiple sclerosis. The research project is scheduled to be completed by Aug 31, 2026. As a leading public research university, the University of Toronto has a history of...
The federal Project Grant award of $438,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research conducted by the Provincial Health Services Authority in Canada, operating under the name BC Cancer, to decode and target genomic instability in pediatric osteosarcoma. The project, with a period of performance from September 30, 2023 to September 29, 2025, aims to develop innovative solutions for cancer treatment,...